Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Asset Writedowns and Impairment (2016 - 2025)

Apyx Medical's Asset Writedowns and Impairment history spans 15 years, with the latest figure at $218000.0 for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 113.73% year-over-year to $218000.0; the TTM value through Dec 2025 reached $423000.0, up 159.51%, while the annual FY2025 figure was $423000.0, 159.51% up from the prior year.
  • Asset Writedowns and Impairment reached $218000.0 in Q4 2025 per APYX's latest filing, up from $33000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $218000.0 in Q4 2025 to a low of -$142000.0 in Q1 2023.
  • Average Asset Writedowns and Impairment over 5 years is $65400.0, with a median of $46500.0 recorded in 2021.
  • The largest YoY upside for Asset Writedowns and Impairment was 12200.0% in 2023 against a maximum downside of 201.43% in 2023.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $71000.0 in 2021, then plummeted by 54.93% to $32000.0 in 2022, then soared by 221.88% to $103000.0 in 2023, then fell by 0.97% to $102000.0 in 2024, then surged by 113.73% to $218000.0 in 2025.
  • Per Business Quant, the three most recent readings for APYX's Asset Writedowns and Impairment are $218000.0 (Q4 2025), $33000.0 (Q3 2025), and $144000.0 (Q2 2025).